| Abstract |
Objective To explore the clinical application effect of high-flow nasal cannula oxygen therapy (HFNC) in patients with acute respiratory distress syndrome (ARDS). Methods 80 ARDS patients admitted to the ICU of our hospital from May 2023 to May 2024 were selected and divided into a control group and an observation group according to the random grouping method, with 40 cases in each group. The control group was treated with traditional Venturi mask oxygen therapy, and the observation group was treated with high-flow nasal cannula oxygen therapy. The blood gas and oxygenation indicators (PaO2, PaCO2, SaO2, PaO2/FiO2), hemodynamic parameters (MAP, MPAP, CVP, CI), assisted ventilation time, ICU hospitalization time and the occurrence of complications of the two groups of patients were recorded respectively, and conduct statistical analysis. Results After 3 days of treatment, the PaO2 and PaO2/FiO2 of the observation group were significantly higher than those of the control group (P<0.05), and the difference in PaCO2 between the two groups was not statistically significant (P>0.05). The assisted ventilation time and ICU hospitalization time of the observation group were significantly shorter than those of the control group (P<0.05). The reintubation rate and 28-day mortality rate in the observation group were lower than those in the control group, and the incidence of complications was also significantly lower (P<0.05). Conclusion High-flow nasal cannula oxygen therapy is more effective than traditional venturi mask oxygen therapy in improving the oxygenation status of ARDS patients, shortening assisted ventilation time and ICU stay, and reducing reintubation rate and complication rate. It has important clinical application value.
|